It also targets acute lymphoblastic leukemia (ALL) cells by decreasing the catalytic activity of the topoisomerase I enzyme, activating the p53-dependent apoptotic pathway [134]. The gene discussed is TP53; the disease is acute lymphoblastic leukemia.